51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05214014 (ClinicalTrials.gov) | March 1, 2022 | 29/11/2021 | Treatment of Systemic Sclerosis With Autologous Regulatory ?-cells | Treatment of Patients With Systemic Sclerosis With Autologous Regulatory ?-cells | Systemic Sclerosis | Biological: Autologous Regulatory ?-cells;Other: Standard treatment according to the clinical protocols | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University | Not yet recruiting | 18 Years | 80 Years | All | 30 | Phase 1/Phase 2 | NULL |